We conducted a prospective evaluation of all eosinophilic drug reactions (EDRs) through the Prospective Pharmacovigilance Program from Laboratory Signals at Hospital to find out the incidence and distribution of these entities in our hospital, their causative drugs, and predictors.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• In areas where helminth exposure is uncommon, medication-related drug reactions are a common cause of persistent peripheral eosinophilia.
• Eosinophilic drug reactions have a diversity of presentations, which range from benign and self-limited to severe and lifethreatening.
• The systemic disease, affecting multiple organs, is classically exemplified by drug reaction with eosinophilia and systemic symptoms.
WHAT THIS STUDY ADDS
• The main predictor of severity of eosinophilic drug reactions was an early severe eosinophilia.
• A thorough investigation of prodromal symptoms that usually precede exanthema by up to 4 weeks and close patient follow-up to achieve early drug reaction with eosinophilia and systemic symptoms diagnosis and early detection of complications is essential in patients with early severe eosinophilia.
Introduction
In areas where helminth exposure is uncommon, medicationrelated drug reactions are a common cause of persistent peripheral eosinophilia. In the absence of other systemic involvement, this condition generally constitutes a benign drug effect that can be caused by a myriad of medication classes. Drugs commonly associated with benign eosinophilia include penicillin and sulphonamide drugs [2] .
Nevertheless, the finding of eosinophilia is of limited value in the determination of whether the reaction is drug induced. In a broad evaluation of inpatient adverse cutaneous drug reactions, only 18% had peripheral eosinophilia (>700 × 10 6 cells l À1 ) [3] . Eosinophilic drug reactions (EDRs)
have recently been described as a type IVb reaction [4] , which involves a Th2-mediated immune response with secretion of IL-4, IL-13, and IL-5. IL-5 is known to be the key factor in regulating the growth, differentiation, and activation of eosinophils. Eosinophil activity is also augmented by Th1 cytokines, including IL-3 and granulocyte-macrophage colony-stimulating factor (GM-CSF) [5] [6] [7] [8] . There are numerous types of EDR, ranging from benign, asymptomatic eosinophilia to potentially fatal reactions resulting in organ damage. The extent of clinical involvement is also heterogeneous, ranging from isolated peripheral eosinophilia or single organ involvement (skin, lung, kidney, liver) to systemic disease affecting multiple organs, classically exemplified by drug reaction with eosinophilia and systemic symptoms (DRESS). Given the multitude of clinical patterns associated with eosinophilic drug allergy, the diagnosis can be challenging. Our knowledge of these presentations is currently limited, but the potential for severe reactions should be considered to facilitate diagnosis and establish appropriate therapy at an early stage of the disease. Diagnosis is not easy because of the different times at which each symptom appears, which hides the severity of the condition. The Pharmacovigilance Program from Laboratory Signals at Hospital (PPLSH) is a programme based on the systematic detection of predefined abnormal laboratory values (automatic laboratory signal [ALS]), using the laboratory information system of the hospital. PPLSH has been useful for the early detection and evaluation of specific severe adverse drug reactions (ADRs) [9] . The aim of this study was to detect all forms of drug hypersensitivity associated with peripheral eosinophilia, hospital acquired or community acquired, through a PPLSH in all hospitalised patients over a period of 42 months.
Materials and methods

Setting
La Paz University Hospital in Madrid, Spain, is a tertiary-care teaching facility. During the 42 months of the study (February 2012 to August 2015, except August 2014), all admissions were monitored by the PPLSH [9] in accordance with the Spanish Personal Data Protection Law [10] . PIELenRed (una plataforma para la investigación de las reacciones cutáneas graves, a platform for the investigation of severe skin reactions) approval was obtained from the appropriate Institutional Review Board. All eosinophilic drug reaction cases were reported to the Spanish pharmacovigilance system. Drugs were categorised by active ingredient using the Anatomical Therapeutics Chemical classification system.
Information system and coverage
A specific database application was developed within the Integrated Laboratory System (Labtrack ® , Woolloomooloo, Australia) to detect predefined ALS, which was retrieved systematically. When we detected a signal in a hospitalised patient, hospital acquired or community acquired, a systematic review of the patient's electronic medical record was performed, including laboratory, microbiological, immunological, and imaging tests as well as drugs administered both at home and in hospital.
Definition of signal
The criterion for eosinophilia was a total count of eosinophils >700 × 10 6 cells l À1 [11] . Hospital laboratories performing blood tests on inpatient and emergency patients are certified and accredited under the appropriate International Standards Organisation (ISO 9001:2000 and ISO 15189).
Definition of ADR
The International Conference on Harmonisation E2D definition of ADR was used [12] . Medical errors, considered any in written prescription, dispensation, or administration, were excluded.
Procedure for ADR detection and evaluation
Phase I On-file laboratory data for all admissions were screened: 24 h per day, 7 days per week to find eosinophilia. If a single isolated elevated eosinophil count was retrieved, the laboratory performed an assessment, and if eosinophilia was confirmed, a case-by-case basis evaluation was made. Repeated ALS for the same patient on consecutive days with no normal eosinophil count between were discarded, except the first. Phase II The patient's files, including electronically available microbiological, immunological, and imaging results and medical reports were reviewed. The patients, who had eosinophilia upon arrival to the emergency wards (general, trauma, obstetric or paediatric) but who were not admitted to hospital, were discarded from the PPLSH, except those who died in the emergency wards. Those patients with eosinophilia upon arrival to the emergency wards who were admitted to hospital were included in the PPLSH, as well those hospitalised patients with hospital-acquired eosinophilia. When a clear alternative cause was ascertained, the case was considered nondrug related. Alternative causes were evaluated on a case-by-case basis. Phase III For the remaining cases, one or two of the authors performed a detailed review of patient's paper charts. Whenever possible, we interviewed the attending physician and the patient and/or their relatives to obtain more details (e.g., the start date or approximate start date of every medication in current treatment); if necessary, further tests (herpes virus DNA and antibodies, including human herpesvirus 6 [HHV6], serum levels of gamma globulin, or biopsy) were performed according to the attending physician's criteria. Determination of HHV6 and immunoglobulin levels was recommended at the time of the DRESS diagnosis, before the onset of steroid therapy, and at the discharge. Changes in serum levels of gamma globulin were calculated. HHV6 antibodies were determined by indirect immunofluorescence assay; dilutions starting at 1:320 were considered positive and dilutions above 1:80 and below 1:160 were considered doubtful. Gamma globulin levels were measured by serum protein electrophoresis. The definition of hypogammaglobulinaemia was a count below the lower limit of normal.
Collection of patient data and reporting When a patient was categorised as having a drug-induced eosinophilia, a complete adverse reaction report was submitted to the pharmacovigilance centre in Madrid.
Diagnosis validation of potential DRESS
Potential DRESS syndrome was diagnosed when the case was evaluated as probable or definitive (a score of 4 or more), using the scoring system proposed by Kardaun et al. [13] Cases included in PIElenRed were at the same time included in the RegiSCAR study group, which validated the potential cases as definite, probable, or possible by the PIELenRed consortium or by RegiSCAR.
Assessment of causality
The causality assessment was performed using the algorithm of the Spanish pharmacovigilance system [14] . This algorithm evaluates the following parameters: the chronology referred to as the interval between drug administration and effect, the literature defining the degree of knowledge of the relationship between the drug and the effect, the evaluation of drug withdrawal, the rechallenge effect, and the alternative causes. The final case evaluation is listed as improbable (not related), conditional (not related), possible (related), probable (related), or definitive (related). Alternative causes were evaluated as a practical approach [15] . For asymptomatic drug-induced eosinophilia, a careful history was taken and a case-by-case basis evaluation was made to attempt to elucidate the sequence of events from the introduction of a new treatment to the discovery of eosinophilia and/or the appearance of symptoms. In acute cases, identification of the offending agent was based on the chronology of drug initiation as well as the type of molecule itself (e.g. antibiotics, antiepileptics). In nonacute cases, the evaluation was more challenging, and we proceeded by trial and error. If, after withdrawal, the dechallenge effect appeared within 30 days and other causes were ruled out, an asymptomatic eosinophilic drug reaction was accepted. We recommended withdrawal of any drug that was not crucial for the patient's well-being. In cases of immunosuppressive therapy or antineoplastic treatment, monitoring of the clinical evolution was recommended without withdrawing the suspected drug. If a symptomatic eosinophilia drug-induced reaction developed, cessation of drug administration was warranted. For DRESS, a suggestive chronology was considered if the drug was initiated less than 6 months previously and was stopped in less than 14 days before the index day. In DRESS cases, the exanthema index day was the day in which the exanthema appeared, and the prodromal index day was the day in which the first symptom or sign occurred. Drug causality for DRESS syndrome patients was additionally established by allergological study, including a lymphocyte transformation test (LTT), and epicutaneous, prick, and intradermal (ID) tests [16, 17] .
Data analysis
The in-hospital incidence rate of eosinophilia was calculated by dividing the number of cases of drug-induced reactions by the number of hospitalised patients obtained from the hospital management service during the 42 selected months. 
Results
Over the 42 months of the study, there were 164 379 admissions to hospital; of these, 3233 cases of eosinophilia were detected. Table 1 shows the number of cases, percentages, incidence rates, and CIs of incidence rates corresponding to the diagnoses causing eosinophilia. A total of 274 cases of eosinophilia in 267 patients were categorised as ADR. The incidence rate for 10 000 patients during the period of the study was 16.67 (CI 95%: 9.90-25.98). Of these, 106 (39.7%) cases were community acquired and 216 (78.8%) cases were hospital acquired. The general demographics and admission wards of the population with drug-induced eosinophilia are shown in Table 2 .
Asymptomatic eosinophilia
Out of 274 cases of drug-induced eosinophilia, 154 cases in 148 patients were isolated peripheral blood eosinophilia. Of these, 70 (47.3%) cases were community acquired. The latency time (median, range) to onset of eosinophilia was 6 days (1-21 days). The peak (median, range) of eosinophil count was 760 × 10 6 cells l À1 (722-2300 × 10 6 cells l À1 ) Table 2 shows the demographics of the cases. The most frequent causal therapeutic group was anti-infectives for systemic use (58 cases), primarily beta-lactam drugs, the most frequent being enalapril and filgrastim (five cases each), followed closely by multiple drugs. The drugs associated with benign eosinophilia are shown in Table 3 .
Symptomatic eosinophilia
The remaining 120 cases showed other involvement. Of these, 36 (30.0%) cases were community acquired. The peak Drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome Twenty-two of 64 cases of potential DRESS (34.4%) were community cases, whereas in 42 (65.6%) cases, the reaction started during the hospitalisation. The incidence rate for 10 000 patients during the period of the study was 3.89 (CI 95%: 1.09-8.77). One case was classified as overlapping with possible Stevens-Johnson syndrome (benznidazole), and one case was diagnosed as overlapping with possible acute generalised exanthematous pustulosis (benznidazole). Table 2 shows the demographics of the cases. The most frequent symptoms were skin involvement (100%), fever ≥38.5°C (86%), and influenza-like symptoms (67%). The cases' characteristics are shown in Table 4 . Progression of DRESS signs or symptoms was sequential in all cases. The latency of the same sign or symptom can vary up to 56 days for eosinophilia (median, 21 days) or visceral involvement (median, 20 days), and up to 28 days for hypogammaglobulinaemia (median, 12 days) or fever (median, 11 days).
The prodromal stage, defined as the period between the onset of the reaction and the start of the exanthema, lasted up to 4 weeks (median 7 days, range 0-28 days), 9 days in PIELenRed cases (median 1 day, range 0-9 days). Early signs, such as haematological or asymptomatic organ involvement can be present up to 28 days before; in addition, signs and symptoms such as fever, lymphadenopathy, pruritus, influenza-like symptoms, or skin pain can be evident 2 weeks before (Figure 1 ). This stage might contribute to the longer latency time in DRESS compared with other SCARs.
The 42 DRESS cases that developed during hospitalisation were evaluated to assess the predictive signs or symptoms. A positive correlation was found between eosinophil count and serum levels of alanine aminotransferase (R = 0.946; P < 0.001; Figure 2A ). Furthermore, eosinophil count positively correlated with longer periods of hospitalisation (R = 0.729; P < 0.01; Figure 2B ). These data indicate that circulating eosinophil levels might be closely related to disease severity in patients with DRESS. Longitudinal analyses indicated that the increased eosinophil count decreased significantly after treatment with corticosteroids ( Figure 2C) ; although all the patients received corticosteroid treatment after diagnosis of drug eruption, we focused on the cumulative dose of corticosteroids in DRESS (R = 0.493; P < 0.05). These data suggest that eosinophil count correlates with the severity of the drug eruption; thus, eosinophil count might be a promising predictor of the severity of DRESS. Moreover, in cases in which hypogammaglobulinaemia was detected, a reactivation of HHV-6 was subsequently detected (R = 0.931; P < 0.001; Figure 2D ). This association was not limited to anticonvulsant causality. We ruled out the possibility of an association between hypogammaglobulinaemia and glucocorticoid therapy because Ig levels were measured before the onset of steroid therapy.
Drug causality in DRESS was assessed for a total of 517 drugs. The number of suspect drugs was substantially reduced after elimination as a result of the time course. All the patients who took drugs known to cause DRESS had nonsuggestive chronology because of long-term use (>6 months) or long-time withdrawal (>14 days) were exposed to another drug within the chosen time window. Probable causality was concluded in all cases. In the DRESS cases that developed during hospitalisation, antibiotics were the most frequent culprits; and for DRESS causing hospitalisation, antiepileptics, allopurinol, azathioprine, and benznidazole were the most frequent causal drugs. Latency time to exanthema index day (median, range) was 23 (3-86) days. Latency time to prodromal index day (median, range) was significantly shorter at 15 (3-58) days, P < 0.05. Two patients experienced accidental re-exposure to vancomycin and piperacillin/tazobactam, 2 years and 7 months later, respectively; they developed a maculopapular rash and an increase in liver enzymes hours after a unique dose. Of 64 cases, 34 were studied at the allergy department after discharge and at least 4 weeks after discontinuation of treatment with corticosteroids and resolution of the DRESS syndrome. The following allergy tests were performed: the LTT, epicutaneous prick, and ID tests. Of 34 cases, LTT results were positive for the culprit drug in all cases except azathioprine, probably because of the immunosuppressive effect of the drug. LTTs were also performed with other β-lactams or other aromatic antiepileptic drugs to define a possible cross-reactivity. Only 23.5% (9/34) of patients had a positive ID, and only 14.7% (5/34) of patients had a positive patch test.
Discussion
The number of eosinophils is normally tightly regulated in the human body. In healthy people, the eosinophil count is only a minority of peripheral blood leukocytes, and their presence in tissues is primarily limited to gastrointestinal mucosa [18] .
However, under certain conditions, eosinophils can selectively accumulate in peripheral blood or in tissue [19] . Any perturbation that results in eosinophilia has profound clinical effects. In our series, the leading cause of eosinophilia was convalescence of viral, bacterial, or protozoal infections followed by preterm neonates, solid malignancies, followed by drugs. It is well established in the literature that a marked accumulation of eosinophils occurs in several disorders, such as convalescence of infections, parasitic infections, and cancer [15, [19] [20] [21] . Eosinophilia in preterm newborns has been known for 6 decades [22] . The neonatal intensive care unit of our hospital receives approximately 1500 premature newborns per year; thus, our results show a high incidence for this cause of eosinophilia.
In absence of other systemic involvement, isolated peripheral blood eosinophilia is a benign drug effect that can be caused by a myriad of medication classes. It might be a direct physiologic effect of certain cytokine therapies (IL2, GM-CSF) secondary to expansion of IL-5-producing T cells; however, the mechanisms underlying most instances of drug-related eosinophilia have not been elucidated [2] . In our series, asymptomatic eosinophilia by drugs was more frequently observed than symptomatic eosinophilia (154 vs. 120). Our findings support current expert opinion regarding its frequency [23] . Among symptomatic eosinophilia cases, the most frequent cause was DRESS (64 cases, 53%), followed by eosinophilia with only dermatological symptoms (36 cases, 30%), and then with visceral involvement (19 cases, 16%). Substantial tissue damage is unlikely to occur with a low eosinophil count, and expert opinion supports that isolated eosinophilia must be monitored; withdrawal of any drug that is not crucial for the patient is recommended [24] . Drug-induced eosinophilia, however, frequently prompts clinical concern regarding impending organ involvement. Our data have shown that the development of symptoms after eosinophilia onset was more likely with earlier onset of eosinophilia, higher eosinophil count, and a delayed onset of corticosteroids. Kimberly et al. [25] , in a prospective cohort study of 824 patients receiving prolonged intravenous antibiotic therapy as outpatients, found that the patients with eosinophilia had a significantly higher likelihood of rash (adjusted HR, 4.16; 95% CI: 2.54-6.83) or renal injury (HR, 2.13; 95% CI: 1.36-3.33), compared with the patients without eosinophilia. However, DRESS syndrome only occurred in seven patients. Finally, our data support that DRESS syndrome can occur at a higher frequency than previously reported in the drug-induced eosinophilia literature [26] . The finding of eosinophilia is a diagnostic challenge in clinical practice. The treating physician immediately wonders if the condition is drug induced, which drug is causing it, if it will be benign or symptomatic, and if it will be necessary to withdraw the agent and to initiate corticosteroids. Previous in vivo and in vitro data indicate that eosinophils are particularly involved in patients with DRESS syndrome [27, 28] . DRESS is a distinctive reaction, first described during treatment with anticonvulsant drugs (most commonly carbamazepine), and subsequently with a multitude of medication classes. However, antiepileptic medications remain the predominant cause of DRESS, with an incidence of 1 per 5000 to 10 000 exposures [29] . The DRESS incidence rate for 10 000 patients during the period of the study was 3.89. There are no other available data in the literature about the incidence of this syndrome in Spain. Antibiotics were the most frequent culprits during hospitalisation but allopurinol, antiepileptics, azathioprine, and benznidazole were the most frequent causal drugs in DRESS causing hospitalisation.
The actual definition of DRESS was proposed by Bocquet et al. in 1996 [30] and updated in 2007 by the Registry of Severe Cutaneous Adverse Reactions (RegiSCAR) Study Group [13] . DRESS syndrome diagnosis is complex due to the wide variety of signs and symptoms not all present at the same time in the patient [4, [31] [32] [33] . The phenotype of the skin is imprecise; the most common presentation is polymorphous maculopapular (85%); however, monomorphic (15%), pustules (30%), and purpura (26%) also occur. Hypereosinophilia was present in 95% of cases. Other haematological Figure 1 Successive signs and symptoms since drug exposure (3 weeks-3 months), onset of the exanthema (index day, 0 d) and human herpesvirus 6 replication in drug reaction with eosinophilia and systemic symptoms patients manifestations were atypical lymphocytes (67%) and lymphadenopathy (54%). Internal organ involvement has been reported in 91% of cases, primarily due to hepatic injury (elevation of liver function tests or hepatomegaly). Other frequent symptoms were high fever (90%) and mild mucosal involvement (56%) [34] . All the data are in concordance with our results except mild mucosal involvement, which was lower in our series (42%). The pathogenesis is unclear, but is most likely to involve several aspects, including a network of drug metabolites, specific HLA alleles, herpes viruses (EBV, HHV-6, HHV-7, or CMV), and immune system activation [35] .
The results of PPLSH showed that the patients with higher peripheral blood eosinophilia had poorer liver function, prolongation of hospitalisation, and higher cumulative doses of corticosteroids. Yang et al. [36] found that eosinophil count in patients with an erythema multiform-type drug eruption was associated with severe disease. In the RegiSCAR scoring system proposed by Kardaun et al. [34] for diagnosis of DRESS, the score increases with the degree of eosinophilia from one point if eosinophilia is between 700 and 1499 × 10 6 cells l À1 , to two points if eosinophilia is >1500 × 10 6 cells l À1 .
The association between hypogammaglobulinaemia and DRESS has been previously reported. In a retrospective study,
Figure 2
Eosinophil count and drug reaction with eosinophilia and systemic symptoms severity were positively correlated in patients. Comparisons between eosinophil count and serum alanine aminotransferase levels (A), days of hospitalisation (B), cumulative corticosteroid usage (prednisone, mg) (C). Changes (%) in serum levels of immunoglobulin classes were positively correlated with reactivation of human herpesvirus 6 (immunofluorescence assay) (D). Drug reaction with eosinophilia and systemic symptoms cases occurring during hospitalisation (n = 42) Boccara et al. [37] found that the hypogammaglobulinaemia significantly associated with DRESS was not limited to carbamazepine, but also with other anticonvulsants (phenytoin, phenobarbital) and with other drugs (allopurinol, piperacillin/tazobactam, ibuprofen, celecoxib, vancomycin). This transient immune dysfunction might be a consequence of the severe depletion of B cells observed at the beginning of the DRESS induced by drugs in a predisposed genetic background [38] . Most of the drugs associated with DRESS exhibit immunomodulatory properties (e.g., allopurinol, anticonvulsants, anti-infectives, anti-inflammatory drugs, azathioprine, benznidazole, sulfasalazine); the consequence can be herpesvirus reactivation, including HHV-6 associated with DRESS. This reactivation occurs at the very beginning of DRESS, when the clinical symptoms are similar to mononucleosis syndrome, and during the subsequent flares of DRESS. The evolution of signs and symptoms were sequential in all our DRESS cases, as described previously, but with wide variation depending on the case. The usual sequence presentation according to median data was fever (11 days), hypogammaglobulinaemia (12 days), eosinophilia (21 days), visceral involvement (20 days), and exanthema (23 days). These prodromal symptoms are of utmost importance for differentiating asymptomatic eosinophilia of from DRESS syndrome and predicting its degree of severity. Our results are a helpful contribution to this field.
This study has several limitations. The study was performed at a single centre. It is possible that some drug-induced eosinophilia cases were missed during the process of attributing alternative causes through electronic medical record review (phase II), although this possibility is low given that the alternative causes presented are well known.
Conclusions
The spectrum of eosinophilic drug reactions and the classes of medication associated with peripheral eosinophilia are expanding. Half (53.3%, 64/120 cases) of symptomatic eosinophilic drug reactions were potential DRESS cases, with higher numbers of cases during hospitalisation than in the community. Predictors of symptomatic druginduced eosinophilia reactions were earlier onset of eosinophilia, higher eosinophil count and a delayed onset of corticosteroids. Higher eosinophil count in patients with DRESS was significantly associated with greater impairment of liver function, prolonged hospitalisation, and higher cumulative doses of corticosteroids. In DRESS cases inwhich hypogammaglobulinaemia was assessed, a reactivation of HHV-6 was subsequently detected. Due to variable clinical presentation, the potential for serious reactions should be considered to facilitate diagnosis and institute appropriate management. In patients with higher eosinophilia, a thorough investigation of prodromal symptoms that usually precede exanthema by up to 4 weeks is essential and close follow-up of these patients is necessary to achieve early DRESS diagnosis and early detection of complications.
